Abstract:Objective To detect serum levels of estrogen,FSH and LH of perimenopausal and postmenopausal women with depressive disorder and observe clinical therapeutic effect of estrogen therapy(ET) on depressive disorder of the perimenopausal and postmenopausal women.Methods Serum levels of estrogen,FSH and LH of 30 perimenopausal and postmenopausal women with depressive disorder and 30 normal perimenopausal and postmenopausal women were detected by using magnetism-ELISA.44 perimenopausal and postmenopausal women with depressive disorder received 2.5mg/day of tibolone(estrogen) for two weeks and a maintainence dose of 1.25mg/day from the third week for 6 weeks(estrogen alone group),and other 40 perimenopausal and postmenopausal women with depressive disorder received combination of same dose of estrogen and 20mg of paroxitin(an antidepressant) at the same time(combination treatment group).23 women lost in the trail.Hamilton Depression Rating Scale(HDRS) was used to evaluate therapeutic effect for depressive disorder of the women and Kupperman index(KMI) was used to evaluate perimenopausal and postmenopausal symptoms of the women at baseline and the eighth week of treatment(end of the trail).Results The serum level of estrogen of perimenopausal and postmenopausal women with depressive disorder was lower than that of those normal perimenopausal and postmenopausal women(P<0.05).No difference was found in FSH and LH between the two groups.All the women in the two groups showed a significant reduction in HDRS and KMI scores at the end of the 8-week trial(both P<0.01).In the combined treatment group,HDRS score decrease rate was 70.53% and that in the estrogen alone group was 58.24%,and there was a significant difference between the two groups(P<0.05).The total effective rate for depressive disorder in the combined treatment group was 93.33% and that in the estrogen alone group was 80% and there was no significant difference between the two groups(P>0.05).In the combined treatment group,KMI score decrease rate was 73.99% and that in the estrogen alone group was 70.66%,and there was no significant difference between the two groups(P>0.05),and the total effective rate for perimenopausal and postmenopausal symptoms in the combined treatment group was 93.33% and that in the estrogen alone group was 80% and there was no significant difference between the two groups(P>0.05).Conclusion Perimenopausal and postmenopausal depressive disorder is correlated with decreased serum estrogen level of the women.So,estrogen is effective for perimenopausal and postmenopausal women with depressive disorder.Combination of antidepressant and estrogen is the best solution for perimenopausal and postmenopausal depressive disorder,but the treatment should be individualized.

Tripterygium glycosides-induced amenorrhea

Symptom control after different duration of triptorelin treatment following conservative surgery for deep infiltrating endometriosis Post-hoc analysis of a multicentre, prospective, real-world study

The Efficacy and Safety of Triptorelin-Therapy Following Conservative Surgery for Deep Infiltrating Endometriosis A Multicenter, Prospective, Non-Interventional Study in China

Tripterygium Glycosides Impairs the Proliferation of Granulosa Cells and Decreases the Reproductive Outcomes in Female Rats.

A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea

Effect of Tripterygium Glycosides Combined with Hormones on Adult NS Glucocorticoid Resistance and HSP90

Clinical efficacy and safety of trimonthly administration of goserelin acetate 10.8 mg in premenopausal Chinese females with symptomatic adenomyosis: a prospective cohort study

Nylestriol Replacement Therapy in Postmenopausal Women. A Three-Year Prospective Study.

Dynamics of symptoms of genitourinary menopausal syndrome and the frequency of recurrence of lower urinary tract infection in women in periand postmenopausal patients with combined therapy with Trioginal®

Endometrial safety and bleeding pattern during a five-year treatment with long-cycle hormone therapy

[Clinical efficacy and safety of gonadotropin releasing hormone agonist combined with estrogen-dydrogesteronea in treatment of endometriosis]

Long-term post-menopausal hormone therapy and serum HDL-C, total cholesterol and triglycerides

Prednisone Combined with Tripterygium Glycosides in the Treatment of Membranous Lupus Nephropathy

Effects on the Male Endocrine System of Long-term Treatment with Gonadotropin-releasing Hormone Agonists and Estrogens in Male-to-Female Transsexuals

Toxic effects of Tripterygium glycoside tablets on the reproductive system of male rats by metabolomics, cytotoxicity, and molecular docking

Low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for successful long-term management of adenomyosis associated with cerebral venous and sinus thrombosis from low-dose oral contraceptive use

Medicinal intervention in patients with iatrogenic premature ovarian failure after myeloablative treatment followed by hematopoietic stem cell transplantation

A randomized study comparing the side effects and hormonal status of triptorelin and leuprorelin following conservative laparoscopic surgery for ovarian endometriosis in Chinese women

Clinical trial of tripterygium wilfordii polyglycoside in the treatment of patients with IgA nephropathy

Effect of estrogen on depressive disorder of perimenopausal and postmenopausal women

Effects of Triptolide-Medicated Serum on Secretion Function of Adrenocortical Cells Isolated from Rats